This clinical trial aims to determine whether Meu-cinn promotes gastric mucosal health in adults with functional dyspepsia and to assess its safety.
The main questions are:
* Does Meu-cinn promote gastric mucosal health in participants? * What side effects occur when participants take Meu-cinn?
Rome IV-based functional dyspepsia-
Patients with gastrointestinal symptoms requiring immediate drug treatment.
Individuals with a history of hypersecretory gastric disorders like Zollinger-Ellison syndrome.
Individuals who received Helicobacter pylori eradication therapy within 4 weeks prior to the trial.
Individuals who have taken nonsteroidal anti-inflammatory drugs, steroids, antibiotics, aspirin, antithrombotic agents, or acid suppressants within the last month.